MPR delivers practical, up-to-date drug information to healthcare professionals. Using the expertise gained from 25 years of providing point-of-care drug tools, MPR has now created a drug review course exclusively for See below for a list of each quarter's courses. Click here to visit MPR's website.

Latest Courses

MPR Drug News

For Some Older Adults, Anticholinergics May Provide Cognitive Benefits

Older adults with questionable cognitive impairment exposed to anticholinergics demonstrated higher global cognitive scores compared to those not exposed to anticholinergics, according to a study published in Drugs & Aging.

FDA Approval Expands Orkambi Use in Pediatric Patients with Cystic Fibrosis

Vertex announced that the Food and Drug Administration (FDA) has approved Orkambi (lumacaftor and ivacaftor) tablets for use in children with cystic fibrosis aged 6-11 years who have 2 copies of the F508del mutation.

Pregabalin for Generalized Anxiety Disorder: Is it Effective?

A systematic review and meta-analysis published in the journal International Clinical Psychopharmacology found that pregabalin was superior to placebo for the amelioration of generalized anxiety disorder (GAD) symptoms.

Erenumab Reduces Monthly Migraine Days in Phase 3 Study

Amgen announced positive top-line results from their Phase 3 trial ARISE, evaluating erenumab (AMG 334) for safety and efficacy in preventing migraines.

Blood-Based Companion Diagnostic Test for Osimertinib Approved

AstraZeneca announced that the Food and Drug Administration (FDA) has approved cobas EGFR Mutation Test v2, a companion diagnostic for Tagrisso (osimertinib).